Ligelizumab
CQGE031C2303
Phase 3 mab completed
Quick answer
Ligelizumab for Chronic Spontaneous Urticaria is a Phase 3 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Chronic Spontaneous Urticaria
- Phase
- Phase 3
- Modality
- mab
- Status
- completed